Results of anticancer activity of newly synthesized compounds.
| Compounds | Cell culture IC50a [μM] | ||
|---|---|---|---|
| HL-60 | NALM-6 | WM-115 | |
| 1a | 583.9 ± 84.3 | 569.3 ± 21.9 | >1000 |
| 1b | 506.37 ± 47.08 | 468.52 ± 44.36 | 481.29 ± 39.43 |
| 1c | 618.0 ± 32.0 | 152.3 ± 26.7 | 751.5 ± 118.1 |
| 1d | 778.8 ± 125.3 | 614.7 ± 60.9 | 90.91 ± 10.2 |
| 2a | 88.86 ± 6.06 | 51.55 ± 5.71 | 60.24 ± 6.30 |
| 2b | 80.83 ± 3.9 | 40.03 ± 5.59 | 54.88 ± 5.94 |
| 2c | 86.51 ± 8.02 | 11.71 ± 1.62 | 26.66 ± 3.28 |
| 2d | 594.0 ± 52.0 | 491.4 ± 31.0 | 7.99 ± 0.87 |
| Dimer | 400.86 ± 46.22 | 373.89 ± 40.78 | >1000 |
| Cisplatinb | 0.8 ± 0.1 | 0.7 ± 0.3 | 18.2 ± 4.3 |
| Carboplatinb | 4.3 ± 1.3 | 0.7 ± 0.2 | 422.2 ± 50.2 |
a
IC50 values [μM] were calculated at concentration of a tested compound required to reduce the fraction of surviving cell to 50% of that observed in comparison to the control probe, non treated cell. Mean values are presented of parameter IC50 ± SD from 4 experiments.
b
The values for referential compounds can be found in literature.23